Ensysce Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
ENSC$0.36-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(3,556,415) | $(1,945,573) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Accrued interest | 3,089 | 2,947 |
| Change in fair value of liability classified warrants | - | (9,916) |
| Consultant compensation | - | 46,093 |
| Stock-based compensation | 8,743 | 16,251 |
| Depreciation expense | 6,533 | - |
| Changes in operating assets and liabilities: | ||
| Unbilled receivable | 420,345 | 102,113 |
| Prepaid expenses and other assets | 1,292,926 | 433,659 |
| Accounts payable | (1,663,513) | (741,784) |
| Accrued expenses and other liabilities | (12,633) | 388,798 |
| Net cash used in operating activities | (3,500,925) | (1,707,412) |
| Cash flows from financing activities: | ||
| Proceeds from public offerings | - | 1,100,006 |
| Proceeds from warrant exercises | - | 347,995 |
| Transaction costs from public offerings | - | (142,950) |
| Repayment of financed insurance premiums | (63,947) | (47,225) |
| Net cash (used in) provided by financing activities | (63,947) | 1,257,826 |
| Decrease in cash and cash equivalents | (3,564,872) | (449,586) |
| Cash and cash equivalents beginning of period | 4,310,354 | 3,502,077 |
| Cash and cash equivalents end of period | $745,482 | $3,052,491 |
| Supplemental disclosure of non-cash financing activities: | ||
| Transaction costs included in accounts payable | $6,090 | $61,243 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.